Drugs / TDENV-LAV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02239614 | Dec 2014 → Feb 2016 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDENV-LAV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02239614 ↗ |
| Modality | Vaccine | “tetravalent dengue virus (DENV-1-4) live attenuated vaccine” PMID 32966573 ↗ May 2021 |
| Route | Subcutaneous | “administered subcutaneously on day 0 of the study” NCT02239614 ↗ |